
CLAIMS

1. Use of a compound having the formula:



or a pharmaceutically acceptable tautomer or salt thereof, in the manufacture of a medicament for treating, preventing, or reducing the risk of a skin infection caused or mediated by *Propionibacterium acnes* or *Gardnerella vaginalis* in a patient.

2. The use according to claim 1, wherein the compound is a pharmaceutically acceptable salt selected from the group consisting of acetate, ascorbate, benzoate, citrate, esylate, ethanedisulfonate, fumarate, hydrochloride, lactate, maleate, mesylate, phosphate, pyroglutamate, salicylate, succinate, sulfate, tartrate, and tosylate.

3. The use according to any one of claims 1-2, wherein the skin infection is caused or mediated by *Propionibacterium acnes*.

4. The use according to any one of claims 1-2, wherein the skin infection is caused or mediated by *Gardnerella vaginalis*.

5. The use according to any one of claims 1-4, wherein the skin infection is selected from acne vulgaris, bacterial conjunctivitis, and bacterial vaginosis.

6. The use according to claim 5, wherein the skin infection is acne vulgaris.

7. The use according to claim 5, wherein the skin infection is bacterial vaginosis.

8. The use according to any one of claims 1-7, wherein the medicament is to be administered orally, parentally, or topically.

9. The use according to claim 8, wherein the medicament is to be administered topically.

10. The use according to any one of claims 1 through 9, wherein the patient is a mammal or domestic animal.

11. The use according to any one of claims 1 through 10, wherein the patient is a human.

12. The use according to any one of claims 1 through 11, wherein the compound is to be administered once daily or twice daily.

13. The use according to any one of claims 1 through 12, wherein the compound is to be administered once daily.

14. The use according to any one of claims 1 through 12, wherein the compound is to be administered twice daily.

15. The use according to any one of claims 1 through 14, wherein the medicament is a topical formulation further comprising one or more dermatologically acceptable carriers.